Home
ALKS
ALKS News

Latest Alkermes plc (ALKS) News on December 22, 2024

MT Newswires

12 days ago

Alkermes Insider Sold Shares Worth $1,961,406, According to a Recent SEC Filing

Qiagen (QGEN) Down 1.6% Since Last Earnings Report: Can It Rebound?

Zacks

16 days ago

Qiagen (QGEN) Down 1.6% Since Last Earnings Report: Can It Rebound?

Ultragenyx (RARE) Down 6.8% Since Last Earnings Report: Can It Rebound?

Zacks

17 days ago

Ultragenyx (RARE) Down 6.8% Since Last Earnings Report: Can It Rebound?

MT Newswires

17 days ago

Alkermes Insider Sold Shares Worth $441,550, According to a Recent SEC Filing

Illumina (ILMN) Down 9.3% Since Last Earnings Report: Can It Rebound?

Zacks

18 days ago

Illumina (ILMN) Down 9.3% Since Last Earnings Report: Can It Rebound?

Glaxo (GSK) Down 6.6% Since Last Earnings Report: Can It Rebound?

Zacks

23 days ago

Glaxo (GSK) Down 6.6% Since Last Earnings Report: Can It Rebound?

Why Is Incyte (INCY) Up 2.1% Since Last Earnings Report?

Zacks

24 days ago

Why Is Incyte (INCY) Up 2.1% Since Last Earnings Report?

Axsome Therapeutics eyes approval after Phase III narcolepsy win

Clinical Trials Arena

25 days ago

Axsome Therapeutics eyes approval after Phase III narcolepsy win

Alkermes to Participate in Upcoming Investor Conferences

PR Newswire

a month ago

Alkermes to Participate in Upcoming Investor Conferences

Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock?

Zacks

a month ago

Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock?

MT Newswires

a month ago

Alkermes Insider Sold Shares Worth $1,774,576, According to a Recent SEC Filing

Alkermes to Participate in Two Upcoming Investor Conferences

PR Newswire

a month ago

Alkermes to Participate in Two Upcoming Investor Conferences

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences

PR Newswire

a month ago

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences

MT Newswires

2 months ago

Stifel Upgrades Alkermes to Buy From Hold, Adjusts Price Target to $36 From $25

Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down

Zacks

2 months ago

Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down

Alkermes Third Quarter 2024 Earnings: EPS Misses Expectations

Simply Wall St.

2 months ago

Alkermes Third Quarter 2024 Earnings: EPS Misses Expectations

Alkermes PLC (ALKS) Q3 2024 Earnings Call Highlights: Strong Proprietary Product Growth and ...

GuruFocus.com

2 months ago

Alkermes PLC (ALKS) Q3 2024 Earnings Call Highlights: Strong Proprietary Product Growth and ...

Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks

2 months ago

Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say

MT Newswires

2 months ago

Sector Update: Health Care Stocks Flat to Higher Premarket Thursday

Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates

Zacks

2 months ago

Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates

MT Newswires

2 months ago

Alkermes' Q3 Non-GAAP Earnings Rise, Revenue Falls

Associated Press Finance

2 months ago

Alkermes: Q3 Earnings Snapshot

Alkermes plc Reports Third Quarter 2024 Financial Results

PR Newswire

2 months ago

Alkermes plc Reports Third Quarter 2024 Financial Results

Alkermes PLC (ALKS) Q3 2024 Earnings Report Preview: What to Expect

GuruFocus.com

2 months ago

Alkermes PLC (ALKS) Q3 2024 Earnings Report Preview: What to Expect

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks

2 months ago

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Zacks

2 months ago

Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Alkermes to Report Third Quarter Financial Results on October 24, 2024

PR Newswire

2 months ago

Alkermes to Report Third Quarter Financial Results on October 24, 2024

Alkermes Stock Jumps Nearly 30% In 3 Months After Hefty Profits

Investor's Business Daily

2 months ago

Alkermes Stock Jumps Nearly 30% In 3 Months After Hefty Profits

Is Alkermes (ALKS) The Most Undervalued Quality Stock To Buy According To Analysts?

Insider Monkey

2 months ago

Is Alkermes (ALKS) The Most Undervalued Quality Stock To Buy According To Analysts?

Here's Why Alkermes (ALKS) is a Strong Momentum Stock

Zacks

2 months ago

Here's Why Alkermes (ALKS) is a Strong Momentum Stock

Here's Why Alkermes (ALKS) is a Strong Growth Stock

Zacks

2 months ago

Here's Why Alkermes (ALKS) is a Strong Growth Stock

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Zacks

2 months ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Alkermes (NASDAQ:ALKS) shareholder returns have been favorable, earning 62% in 5 years

Simply Wall St.

3 months ago

Alkermes (NASDAQ:ALKS) shareholder returns have been favorable, earning 62% in 5 years

Alkermes to Host Investor Event to Review Orexin Portfolio Strategy

PR Newswire

3 months ago

Alkermes to Host Investor Event to Review Orexin Portfolio Strategy

Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term

Zacks

3 months ago

Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term

Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024

PR Newswire

3 months ago

Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024

Here's Why Alkermes (ALKS) is a Strong Value Stock

Zacks

3 months ago

Here's Why Alkermes (ALKS) is a Strong Value Stock

Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference

PR Newswire

3 months ago

Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference

Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program

PR Newswire

3 months ago

Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program

Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?

Zacks

4 months ago

Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?

Here's Why Alkermes (ALKS) is a Strong Growth Stock

Zacks

4 months ago

Here's Why Alkermes (ALKS) is a Strong Growth Stock

Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?

Zacks

4 months ago

Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?

Why Alkermes (ALKS) is a Top Value Stock for the Long-Term

Zacks

4 months ago

Why Alkermes (ALKS) is a Top Value Stock for the Long-Term

Why Is Qiagen (QGEN) Down 0.3% Since Last Earnings Report?

Zacks

4 months ago

Why Is Qiagen (QGEN) Down 0.3% Since Last Earnings Report?

Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue?

Zacks

4 months ago

Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue?

Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

PR Newswire

4 months ago

Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Alkermes (ALKS) Down 0.2% Since Last Earnings Report: Can It Rebound?

Zacks

4 months ago

Alkermes (ALKS) Down 0.2% Since Last Earnings Report: Can It Rebound?

Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680

Zacks

4 months ago

Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680

Alkermes launches Phase II trial of ALKS 2680 for narcolepsy type 2

Clinical Trials Arena

4 months ago

Alkermes launches Phase II trial of ALKS 2680 for narcolepsy type 2

MT Newswires

4 months ago

Alkermes Initiates Phase 2 Trial of ALKS 2680 to Treat Narcolepsy Type 2

Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2

PR Newswire

4 months ago

Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2

We Ran A Stock Scan For Earnings Growth And Alkermes (NASDAQ:ALKS) Passed With Ease

Simply Wall St.

4 months ago

We Ran A Stock Scan For Earnings Growth And Alkermes (NASDAQ:ALKS) Passed With Ease

Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term

Zacks

4 months ago

Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term

Here's Why Alkermes (ALKS) is a Strong Value Stock

Zacks

4 months ago

Here's Why Alkermes (ALKS) is a Strong Value Stock

Why Alkermes (ALKS) is a Top Momentum Stock for the Long-Term

Zacks

4 months ago

Why Alkermes (ALKS) is a Top Momentum Stock for the Long-Term

Here's Why Alkermes (ALKS) is a Strong Growth Stock

Zacks

5 months ago

Here's Why Alkermes (ALKS) is a Strong Growth Stock

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks

5 months ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Why Alkermes (ALKS) is a Top Value Stock for the Long-Term

Zacks

5 months ago

Why Alkermes (ALKS) is a Top Value Stock for the Long-Term

MT Newswires

5 months ago

JPMorgan Adjusts Price Target on Alkermes to $32 From $31, Maintains Neutral Rating

Alkermes' (ALKS) Q2 Earnings Miss Estimates, Revenues Beat

Zacks

5 months ago

Alkermes' (ALKS) Q2 Earnings Miss Estimates, Revenues Beat

MT Newswires

5 months ago

HC Wainwright Adjusts Price Target on Alkermes to $37 From $35, Maintains Neutral Rating

MT Newswires

5 months ago

Baird Adjusts Price Target on Alkermes to $38 From $37, Maintains Outperform Rating

Alkermes (ALKS) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks

5 months ago

Alkermes (ALKS) Reports Q2 Earnings: What Key Metrics Have to Say

Alkermes (ALKS) Lags Q2 Earnings Estimates

Zacks

5 months ago

Alkermes (ALKS) Lags Q2 Earnings Estimates

MT Newswires

5 months ago

Alkermes Q2 Adjusted Earnings Rise, Revenue Falls

Is Alkermes plc's (NASDAQ:ALKS) Latest Stock Performance Being Led By Its Strong Fundamentals?

Simply Wall St.

5 months ago

Is Alkermes plc's (NASDAQ:ALKS) Latest Stock Performance Being Led By Its Strong Fundamentals?

Associated Press Finance

5 months ago

Alkermes: Q2 Earnings Snapshot

Alkermes plc Reports Second Quarter 2024 Financial Results

PR Newswire

5 months ago

Alkermes plc Reports Second Quarter 2024 Financial Results

Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for

Zacks

5 months ago

Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for

Alkermes to Report Second Quarter Financial Results on July 24, 2024

PR Newswire

5 months ago

Alkermes to Report Second Quarter Financial Results on July 24, 2024

Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q2 Release

Zacks

5 months ago

Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q2 Release

MT Newswires

5 months ago

JPMorgan Trims Price Target on Alkermes to $31 From $32, Maintains Neutral Rating

Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar?

Zacks

6 months ago

Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar?

MT Newswires

6 months ago

TD Cowen Initiates Alkermes at Buy With $34 Price Target

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

PR Newswire

6 months ago

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store

Business Wire

6 months ago

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store

New Zealand scraps plan to tax livestock burps, farts

AFP

6 months ago

New Zealand scraps plan to tax livestock burps, farts

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility

The Wall Street Journal

6 months ago

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility

Business Wire

6 months ago

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

UK Unemployment Rises in Sign Inflationary Pressures Cool

Bloomberg

6 months ago

UK Unemployment Rises in Sign Inflationary Pressures Cool

Insider-Owned Growth Companies On The Chinese Exchange In June 2024

Simply Wall St.

6 months ago

Insider-Owned Growth Companies On The Chinese Exchange In June 2024

Here's Why New Toyo International Holdings (SGX:N08) Has Caught The Eye Of Investors

Simply Wall St.

6 months ago

Here's Why New Toyo International Holdings (SGX:N08) Has Caught The Eye Of Investors

Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024

PR Newswire

7 months ago

Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024

Why Is Alkermes (ALKS) Down 2.7% Since Last Earnings Report?

Zacks

7 months ago

Why Is Alkermes (ALKS) Down 2.7% Since Last Earnings Report?

Alkermes to Participate in Two Upcoming Investor Conferences

PR Newswire

7 months ago

Alkermes to Participate in Two Upcoming Investor Conferences

Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024

PR Newswire

7 months ago

Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024

MT Newswires

7 months ago

Cantor Fitzgerald Adjusts Alkermes Price Target to $48 From $43, Maintains Overweight Rating

Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't?

Zacks

7 months ago

Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't?

Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

PR Newswire

7 months ago

Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates

Zacks

8 months ago

Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates

MT Newswires

8 months ago

UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating

Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk

PR Newswire

8 months ago

Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk

MT Newswires

8 months ago

Alkermes's Q1 Earnings, Revenue Grow But Miss Street View

Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks

8 months ago

Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say

Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates

Zacks

8 months ago

Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates

Associated Press Finance

8 months ago

Alkermes: Q1 Earnings Snapshot

Alkermes plc Reports First Quarter 2024 Financial Results

PR Newswire

8 months ago

Alkermes plc Reports First Quarter 2024 Financial Results

How To Trade Biotech Stocks: Can These Three Tips Help You Make More Profits?

Investor's Business Daily

8 months ago

How To Trade Biotech Stocks: Can These Three Tips Help You Make More Profits?

Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

8 months ago

Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1

PR Newswire

8 months ago

Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1

Share on Social Networks: